Loading…
Reported covered position: Leg. Ass't. White House Off. of Leg. Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare Access and CHIP Reauthorization Act of 2015
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Medicare Access and CHIP Reauthorization Act of 2015
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MERCK & CO INC via MERCK & CO, INC.
2015 · third_quarter · 3A
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
Trans-Pacific Partnership, data exclusivity for biologics
Source: Senate LDA
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Intellectual property (general education), patent reform (H.R. 3309, the Innovation Act, S.632, the STRONG Patents Act)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures, Medical Innovation Act (S.320), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
340B (no specific bill), Hepatitis C (general education; no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Innovation for Healthy Americans (no bill number), value of medicines (no specific bill), general pharmaceutical issues
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Senate HELP Innovation Draft (no bill number)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Senate HELP Innovation Draft (no bill number)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
340B (no specific bill), Hepatitis C (general education; no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Innovation for Healthy Americans (no bill number), value of medicines (no specific bill), general pharmaceutical issues
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill),
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill),
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill), tax extenders bill
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Fairness to Pet Owners (S.1200), general animal health issues
Fairness to Pet Owners (S.1200), general animal health issues
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures, Medical Innovation Act (S.320), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues
Intellectual property (general education), patent reform (H.R. 3309, the Innovation Act, S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill); trade ajustment assistance (no specific bill); international trade barriers for beta-agonists (no specific bill)
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill), Medicaid-style rebates in Medicare Part D (no specific bill), Low-income subsidy co-pays in Part D (no specific bill), Independent Payment Advisory Board (S.351, H.R. 351), sustainable growth rate (H.R. 4302), Medicaid (no specific bill)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Non-interference in Medicare Part D (no specific bill), Medicaid-style rebates in Medicare Part D (no specific bill), Low-income subsidy co-pays in Part D (no specific bill), Independent Payment Advisory Board (S.351, H.R. 351), sustainable growth rate (H.R. 4302), Medicaid (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Protecting the Integrity of Medicare Act of 2014
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Protecting the Integrity of Medicare Act of 2014
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), transfer pricing of intangibles (no specific bill), territorial tax system (no specific bill), deferral of taxation of foreign earned income (no specific bill), tax base erosion (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Patent Transparency and Improvements Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Patent reform (H.R. 3309, S.1720)
Patent Transparency and Improvements Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Patent reform (H.R. 3309, S. 1720 )
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill), Medicaid-style rebates in Medicare Part D (no specific bill), Low-income subsidy co-pays in Part D (no specific bill), Independent Payment Advisory Board (S.351, H.R. 351), sustainable growth rate (H.R. 4302), Medicaid (no specific bill)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill)
Safeguarding America's Pharmaceuticals Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Safeguarding America's Pharmaceuticals Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill)
Drug Quality and Security Act (HR 3204)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), Medicare Part B (general education, no specific bill)
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill),
Fairness to Pet Owners (S.1200), general animal health issues
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2015 · fourth_quarter · Q4
Trans-Pacific Partnership, data exclusivity for biologics
Omnibus appropriations bill (general advocacy)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), Medicare Part B (general education, no specific bill)
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill), tax extenders bill
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
340B (no specific bill), Hepatitis C (general education; no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), antimicrobial resistance (general education and DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), Innovation for Healthy Americans (no bill number), value of medicines (no specific bill), general pharmaceutical issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2015 · third_quarter · Q3
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Fairness to Pet Owners (S.1200), general animal health issues
Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill),
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), Medicare Part B (general education, no specific bill)
Trans-Pacific Partnership, data exclusivity for biologics
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2015 · second_quarter · Q2
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Senate HELP Innovation Draft (no bill number)
Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2015 · first_quarter · Q1
340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures, Medical Innovation Act (S.320), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
House of Representatives FY16 Budget Resolution, Senate FY16 Budget Resolution,
Intellectual property (general education), patent reform (H.R. 3309, the Innovation Act, S.632, the STRONG Patents Act)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · 3A
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Additives in beef cattle (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · 3A
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Additives in beef cattle (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · fourth_quarter · 4A
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · 3A
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)
Additives in beef cattle (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · fourth_quarter · Q4
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · Q3
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · second_quarter · Q2
Non-interference in Medicare Part D (no specific bill), Medicaid-style rebates in Medicare Part D (no specific bill), Low-income subsidy co-pays in Part D (no specific bill), Independent Payment Advisory Board (S.351, H.R. 351), sustainable growth rate (H.R. 4302), Medicaid (no specific bill)
Patent reform (H.R. 3309, S.1720)
Education on beta-agonists (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · first_quarter · Q1
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
MERCK & CO INC via MERCK & CO, INC.
2013 · fourth_quarter · Q4
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Drug Quality and Security Act (HR 3204)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2013 · first_quarter · 1A
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2013 · third_quarter · Q3
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill).
Supply chain safety (H.R. 1919, S. 959, S. 957)
MERCK & CO INC via MERCK & CO, INC.
2013 · second_quarter · Q2
Supply chain safety (H.R. 1919, S. 959, S. 957)
Patent settlements (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2013 · first_quarter · Q1
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Alzheimer's education (no specific bill); 340b (no specific bill); hepatitis C education (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2012 · fourth_quarter · Q4
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Hepatitis C education (H.R. 3381); Alzheimer's education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Great Apes (S. 810)
MERCK & CO INC via MERCK & CO, INC.
2012 · third_quarter · Q3
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
MERCK & CO INC via MERCK & CO, INC.
2012 · second_quarter · Q2
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2012 · first_quarter · Q1
Supply chain safety (no specific bill); pharmaceutical shortages (H.R. 2245, S. 296)
Comprehensive Tax Reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
MERCK & CO INC via MERCK & CO, INC.
2011 · fourth_quarter · Q4
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Access to over-the-counter medications (no specific bill)
Korea Free Trade Agreement (H.R. 3080); TranPacific Partnership
MERCK & CO INC via MERCK & CO, INC.
2011 · third_quarter · Q3
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, H.R. 2245)
Patent Reform (H.R. 1249)
MERCK & CO INC via MERCK & CO, INC.
2011 · second_quarter · Q2
Access to over-the-counter medications (no specific bill)
Deficit reduction (no specific bill); WTO Cotton agreement (H.R. 2112); FDA funding (H.R. 2112); ADAP funding (no specific bill)
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and devlopment (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, HR. 2245)
MERCK & CO INC via MERCK & CO, INC.
2011 · first_quarter · Q1
Access to over-the-counter medications (no specific bill)
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill).
Drug shortages
MERCK & CO INC via MERCK & CO, INC.
2010 · first_quarter · 1A
Rx drug importation into the US, other than by drug manufacturer (no specific bill); requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill); promote public/private partnerships for comparative effectiveness assessments (S. 1213); Physician Payments Sunshine Act of 2009 (S. 301); health care reform; increasing coverage of uninsured; coverage of preventative services; including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
Approval and regulation of biosimilars (H.R. 1427; H.R. 1548; S. 726; H.R. 3200; S. 1679; H.R. 4872)
MERCK & CO INC via MERCK & CO, INC.
2010 · fourth_quarter · Q4
Settlement of patent litigation (no specific bill)
Access to over-the-counter medications (no specific legislation).
Increased funding for CDC's National Immunization Program (Sec. 317 Program); Increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2010 · third_quarter · Q3
Use of antibiotics in animals (no specific legislation)
Pharmaceuticals in the environment (HR 5809; S 3397)
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill)
MERCK & CO INC via MERCK & CO, INC.
2010 · second_quarter · 2A
Pharmaceuticals in the environment (no specific legislation)
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
Access to over-the-counter medications (no specific legislation)
MERCK & CO INC via MERCK & CO, INC.
2010 · second_quarter · 2A
Apportionment of damages and post-grant review of patents (S. 515; H.R. 1260). Settlement of patent litigation (no specific bill).
Pharmaceuticals in the environment (no specific legislation)
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
MERCK & CO INC via MERCK & CO, INC.
2010 · second_quarter · Q2
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
Use of antibiotics in animals (no specific legislation)
Pharmaceuticals in the environment (no specific legislation)
MERCK & CO INC via MERCK & CO, INC.
2010 · first_quarter · Q1
RX drug importation into the US, other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Promote public/private partnerships for comparative effectiveness assessment (S. 1213). Physician Payments Sunshine Act of 2009 (S. 301). Health care reform; increasing coverage of uninsured; coverage of preventative services, including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system. (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Efforts to ensure appropriate access to vaccines under Medicare (H.R. 3200; S. 1796; H.R. 3590). Expansion of or increase in Medicaid rebate (H.R. 3200; S. 1796;H.R. 3590; H.R. 4872).
MERCK & CO INC via MERCK & CO, INC.
2009 · fourth_quarter · Q4
Issues related to approval and regulation of biosimilars (H.R. 1427, H.R. 1548, S. 726, HR 3200, S. 1679).
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Support efforts to ensure appropriate access to vaccines under Medicare (HR 3200; S. 1796; H.R. 3590). Oppose expansion of or increase in Medicaid rebate (HR 3200; S.1796; H.R. 3590).
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (S.1213). Issues related to Physician Payments Sunshine Act of 2009 (S. 301). Issues related to health care reform; increasing coverage of uninsured; support efforts to gain coverage of preventive services, including immunizations; prevent 340B pricing expansion; maintaining market-based, private sector health care delivery system. (HR 3200; S. 1679; S. 1796; H.R. 3590)
MERCK & CO INC via MERCK & CO, INC.
2009 · third_quarter · Q3
Issues related to approval and regulation of biosimilars (H.R. 1427, H.R. 1548, S. 726, HR 3200, S. 1679).
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Support efforts to ensure appropriate access to vaccines under Medicare (HR 3200; America's Healthy Futures Act of 2009). Oppose expansion of or increase in Medicaid rebate (HR 3200; American's Healthy Futures Act of 2009).
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (S.1213). Issues related to Physician Payments Sunshine Act of 2009 (S. 301). Issues related to health care reform; increasing coverage of uninsured; support efforts to gain coverage of preventive services, including immunizations; maintaining market-based, private sector health care delivery system. (HR 3200; S. 1679; America's Healthy Futures Act of 2009)
MERCK & CO INC via MERCK & CO, INC.
2009 · second_quarter · Q2
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Support efforts to ensure appropriate access to vaccines under Medicare (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill).
Issues related to approval and regulation of biosimilars (H.R. 1427, H.R. 1548, S. 726).
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (S.1213). Issues related to Physician Payments Sunshine Act of 2009 (S. 301). Issues related to health care reform; increasing coverage of uninsured; maintaining market based, private sector health care delivery system. (no specific legislation)
MERCK & CO INC via MERCK & CO, INC.
2009 · first_quarter · Q1
Issues related to approval and regulation of biosimilars (H.R. 1427, H.R. 1548, S. 726).
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Support efforts to ensure appropriate access to vaccines under Medicare (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill).
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (no specific legislation). Issues related to Physician Payments Sunshine Act of 2009 (S. 301). Issues related to health care reform; increasing coverage of uninsured; maintaining market based, private sector health care delivery system. (no specific legislation)
Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Additives in beef cattle (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill), transfer pricing of intangibles (no specific bill), territorial tax system (no specific bill), deferral of taxation of foreign earned income (no specific bill), tax base erosion (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill)
Deficit reduction (no specific bill)
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill); R&D tax credit (no specific bill).
Patent reform (H.R. 3309, S. 1720 )
Deficit reduction (no specific bill); ADAP funding (no specific bill); omnibus appropriations...
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill); trade ajustment assistance (no specific bill); international trade barriers for beta-agonists (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Patent reform (H.R. 3309)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill)
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Patent settlements (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); hepatitis C education (no specific bill).
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Supply chain safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); additives in beef cattle (no specific bill); treatment of intellectual property in India
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); additives in beef cattle (no specific bill); treatment of intellectual property in India
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Patent settlements (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill)
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Supply chain safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Great Apes (S. 810)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Prescription Drug User Fee Act (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); non-tariff trade barriers on U.S. beef
Access to over-the-counter medications (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Deficit Reduction (no specific bill)
Supply chain safety (no specific bill); pharmaceutical shortages (S. 296, H.R. 2245)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942; S 1577); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Prescription Drug User Fee Act reauthorization (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to immunizations (no specific bills); health literacy (no specific bills); adherence (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Access to over-the-counter medications (no specific bill)
Deficit Reduction (no specific bill); WTO Cotton Agreement (H.R. 2112)
Korea, Panama and Colombia Free Trade Agreements (no specifc bills); TransPacific Partnership
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of teh R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent Reform (H.R. 1249)
Korea, Colombia and Panama Free Trade Agreements (no specific bills); data exclusivity in free trade agrements (no specific bills)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income.
Supplemental examination (S. 23)
Deficit reduction (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation); efforts to ensure appropriate access to vaccines under Medicare (H.R. 3200; S. 1796; H.R. 3590); Expansion of, or increase in, Medicaid rebates (H.R. 3200; S. 1796; H.R. 3590; H.R. 4872)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Access to vaccines.
Pharmaceuticals in the environment (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Access to over-the-counter medications (no specific legislation)
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization. Implementation of the Independent Payment Advisory Board provisions of health care reform bill (H.R. 3590). Reauthorization of the Prescription Drug User Fee Act (no specific bill).
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation). Implementation of the Independent Payment Advisory Board provisions of health care reform bill (H.R. 3590).
Apportionment of damages and post-grant review of patents (S. 515; H.R. 1260). Settlement of patent litigation (S. 3677; S. 369).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Apportionment of damages and post-grant review of patents (S. 515; H.R. 1260). Settlement of patent litigation (no specific bill).
Use of antibiotics in animals (no specific legislation)
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill; FY10 Supplemental Appropriations bill)
End-use of derivatives (H.R. 4173)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
End-use of derivatives (H.R. 4173)
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill; FY10 Supplemental Appropriations bill)
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Access to over-the-counter medications (no specific legislation)
Use of antibiotics in animals (no specific legislation)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
End-use of derivatives (H.R. 4173)
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
Access to over-the-counter medications (no specific legislation)
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Apportionment of damages and post-grant review of patents (S. 515; H.R. 1260). Settlement of patent litigation (no specific bill).
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill; FY10 Supplemental Appropriations bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Approval and regulation of biosimilars (H.R. 1427; H.R. 1548; S. 726; H.R. 3200; S. 1679; H.R. 4872)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office